TrialAmerican journal of hematology2018

A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study.

Lewis L Hsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.